To Discuss The Clinical Effect Of Xuanbai Chengqi Decoction And Sangbaipi Decoction On Acute Exacerbation Of Chronic Obstructive Pulmonary Disease(Syndrome Of Excessive Fu-viscera Caused By Lung-heat) With The Theory Of Treating Lung And Intestine Simulta

Objective: To observe the clinical efficacy of Xuanbai Chengqi Decoction and Sangbaipi Decoction in the treatment of acute exacerbation of chronic obstructive pulmonary disease(syndrome of excessive fu-viscera caused by lung-heat)),evaluate the efficacy and safety of Xuanbai Chengqi Decoction,and explore its possible mechanism from the theory of treating lung and intestine simultaneously.Method: A randomized controlled clinical study was conducted to select out-patients and inpatients from January 2018 to January 2019 in the Department of respiratory medicine of a Chinese medicine hospital.97 patients with acute exacerbation of chronic obstructive pulmonary disease who met the inclusion criteria were excluded from falling out.They were randomly divided into treatment group(49 cases)and control group(48 cases).Relevant clinical data were collected.The control group was given standardized treatment of Western medicine,while the treatment group was given Xuanbai Chengqi Decoction and Sangbaipi Decoction on the basis of standardized treatment of Western medicine.The observation period of the two groups was 2 weeks.At the end of the treatment cycle,data of curative effect indicators(pulmonary function,blood gas analysis,inflammatory indicators,CAT,TCM syndrome integral)were collected for intra-group and inter-group comparison to determine the curative effect.SPSS17.0 software was used for data analysis and statistics,and adverse reaction indicators were routinely detected.Result: 1)Evaluation of curative effect: Xuanbai Chengqi Decoction and Sangbaipi Decoction combined with western medicine in treating ACOPD is superior to the control group in reducing TCM syndrome integral and CAT score,increasing FEV1%,PO2,reducing WBC,N% and CRP,and the results of the two groups are statistically significant(P < 0.05),but there is no statistical difference in PCO 2 reduction between the two groups.Significance(P > 0.05);the total effective rate of the treatment group was higher than that of the control group,and the results of the two groups were statistically significant(P < 0.05).2)Safety evaluation: During clinical observation,there were 3 mild adverse prescriptions of diarrhea in Xuanbai Chengqi Decoction and Sangbaipi Decoction combined with western medicine treatment group.There were no obviousabnormalities in safety test(blood routine,stool routine,liver and kidney function,electrolyte,12-channel electrocardiogram)of the two groups.Conclusion: Under the guidance of the theory of the same treatment of lung and intestine,the results of this clinical trial show that Xuanbai Chengqi Decoction and Sangbaipi Decoction have better clinical efficacy in alleviating clinical symptoms,improving pulmonary function,reducing inflammatory indicators,improving oxygenation and improving oxygenation in the treatment of acute exacerbation of chronic obstructive pulmonary disease of lung-heat-fu syndrome type than that of Western medicine alone.It has good completeness and only slightly controllable adverse reactions,which is worthy of clinical promotion.To provide direction and ideas for the treatment of acute exacerbation of chronic obstructive pulmonary disease with integrated traditional Chinese and Western medicine,and guide clinical practice.However,the theory of lung-intestine co-treatment and the specific mechanism of Xuanbai Chengqi Decoction and Sangbaipi Decoction in this experiment are not completely clear,and further animal and clinical experiments are needed.